Earnings Releases·Nov 5, 2026, 7:10 AM ET

Envoy Medical — Third Quarter 2026 Earnings Summary

Net revenue increased to $66,000 from $42,000 in the prior year period, while the net loss narrowed significantly to $5,240,000 ($0.50 per share) from $7,747,000 ($3.55 per share).
Cash on hand rose to approximately $14.57 million as of September 30, 2026, following $29.997 million in proceeds raised during the nine months ended September 30, 2026.
The Company expects to complete all pivotal clinical trial 12-month visits and Stage 2 data collection by early Q2 2027, with plans to submit the final PMA module shortly thereafter.
Litigation with Atlas Merchant Capital SPAC Fund I LP was terminated via a dismissal agreement on October 6, 2026, with no payment made by the Company.
The Acclaim® cochlear implant achieved the first U.S. pivotal trial milestone of six-month follow-ups for all 56 patients, and the Company anticipates offering a fully implanted option in 2027.